Navigation Links
Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven join forces to combat neurological diseases
Date:5/29/2013

Stellar, the collaboration between Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven, is launched to overcome the inefficiencies in translating basic molecular insights to diagnostics and therapeutics for neurodegenerative diseases. Janssen and Johnson & Johnson Innovation are committing up to 5 million Euros for this project over a five-year period. They will sponsor academic research projects from VIB, KU Leuven and UZ Leuven.

"Developing a new drug takes lots of time, especially for complex diseases such as Alzheimer's. We are convinced that we can increase the chance of success if we, as a research institute, join forces with a pharmaceutical company like Janssen," Johan Cardoen (Managing Director VIB).

"At Janssen Research & Development, we are deeply committed to patients with neurodegenerative diseases and to the health care professionals who care for them," said Husseini Manji, MD, Global Head, Neuroscience. "We believe that collaboration with external innovators is essential to drive the types of discoveries that will bring forth the treatments of tomorrow for neurodegenerative diseases."

"At Johnson & Johnson Innovation, accelerating the most promising early-stage science in collaboration with leading academic centres around the world is how we will continue to make improvements in the health and happiness of people worldwide," commented Patrick Verheyen, head of the Johnson & Johnson Innovation centre in London.

Stellar: joining forces to combat neurological diseases

This innovative collaboration will address the funding gap in Flanders for translational projects and will result in relevant neuroprotective therapeutic strategies by enabling multidisciplinary research projects between basic molecular neuroscientists, experts in cognitive animal model testing, clinical neurologists, human imaging specialists and Janssen R&D scientists.

Stellar seeks to attract top researchers in the BeNeLux scientific community to submit proposals for cutting-edge research in neurodegenerative disorders. The Johnson & Johnson companies will collaborate initially with VIB, KU Leuven and The University Hospital Leuven to create opportunities for collaborative research. Other academic institutions are encouraged to join the project as its next phase begins later this year.

For more information about the initiative and the submission process, please visit http://www.stellar-project.be (available on June 17, 2013).


'/>"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Science, Innovation, and Partnerships for Sustainability -- Symposium May 16-18
2. KU Leuven lab coordinates €9m effort to find new deep-sea drugs
3. UC Berkeley, UCSF and Stanford join forces to help commercialize university innovations
4. Molecular forces are key to proper cell division
5. NJIT and Chinese Tech Institute join forces for 2013 Solar Decathlon in China
6. Scientists join forces to bring plant movement to light
7. Social factors trump genetic forces in forging friendships, CU-led study finds
8. Eurofins MWG Operon reinforces NGS capability with Illumina HiSeq 2500 and Illumina MiSeq
9. New forensic institute at the University of Leicester will help police forces solve unusual crimes
10. University of Leeds and Chinese Academy of Sciences join forces
11. Scientists join forces in call for action to save coral reefs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... and biotech research and development (R&D), today announced the establishment of Genedata Limited ... Managing Director Kevin Teburi, a recognized expert in life science informatics. Creating the ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... facility at its headquarters laboratory in Poway, California. Based upon 12 years ... both in-house personnel and consultants, VetStem constructed and validated a state-of-the-art GMP stem ...
(Date:2/21/2017)... NEW YORK , Feb. 21, 2017   ... US, an international IT solutions and managed services provider ... offering – Service Desk for Epic. The new service ... their internal Epic resources by giving physicians, nurses and ... IT specialists for tier-one support. This will allow hospital ...
(Date:2/20/2017)... ... February 20, 2017 , ... Global relationship ... been approved for full, active membership in the Canadian Direct Sellers Association (DSA) ... Chief Executive Officer Jeff Olson in 2011. Today Nerium International, with ...
Breaking Biology Technology: